Retina

An Analysis of the Effect of ABCA4 p.Asn1868Ile Genotypes on Retinal Structure in 26,558 Participants in the UK Biobank

Mark J. Simcoe,1–4 Gavin Arno,1,2 Pirro G. Hysi,3,4 Tony Ko,5 Michel Michaelides,1,2 Christopher J. Hammond,3,4 Praveen J. Patel,1,2 Omar A. Mahroo,1–4 and Andrew R. Webster1,2; for the UK Biobank Eye and Vision Consortium*

1Institute of Ophthalmology, University College London, London, United Kingdom
2NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology, London, United Kingdom
3Department of Ophthalmology, King’s College London, St Thomas’ Hospital Campus, London, United Kingdom
4KCL Department of Twins Research and Genetic Epidemiology, London, United Kingdom
5Topcon Healthcare Solutions, Inc., Oakland, New Jersey, United States

Correspondence: Andrew R. Webster, UCL Institute of Ophthalmology, 11-43 Bath St, London EC1V 9EL, UK; andrew.webster@ucl.ac.uk.

Received: March 8, 2022
Accepted: April 24, 2023
Published: June 21, 2023


PURPOSE. To determine whether the ABCA4 retinopathy-associated variant p.Asn1868Ile (c.5603A>T) is associated with retinal structure or subclinical disease among the general population.

METHODS. UK Biobank participants of European ancestry with available spectral-domain optical coherence tomography (OCT) passing quality control metrics and exome sequencing data were included. Regression analyses using both linear and recessive models tested for the association between the p.Asn1868Ile variant and total retinal thickness, clinically relevant segmented layer thicknesses, and visual acuity. Further regression analyses were performed with automated quality control metrics to determine if the p.Asn1868Ile variant is associated with poor quality or abnormal scans.

RESULTS. Retinal layer segmentation and sequencing data for the p.Asn1868Ile variant were available for 26,558 participants, following exclusions. We identified no significant association between the p.Asn1868Ile variant and retinal thickness, any of the segmented layers, or visual acuity. There was also no significant difference for homozygous p.Asn1868Ile when tested under the assumption of a recessive model. No association was identified for any of the quality control metrics, and a χ² test showed that participants with the p.Asn1868Ile variant were not more likely to be excluded during quality control due to poor quality scans (P = 0.56).

CONCLUSIONS. The p.Asn1868Ile variant does not appear to affect the retinal structure or have pathogenic or subclinical effects on its own within the general population. The variant is likely to require other specific cis- or trans-acting modifying factors to cause ABCA4 retinopathy.

Keywords: ABCA4, central retinal thickness, inherited retinal diseases

Biallelic pathogenic variants of the human ABCA4 gene cause a spectrum of recessive inherited dystrophies, ranging from those limited to the central macula to others progressing to affect the entire retina and cause complete blindness.1,2 ABCA4 variants cause more inherited disease than any other single gene in most cohorts.3

The ABCA4 (ATP-binding cassette, subfamily A, member 4) gene is expressed in photoreceptors and encodes a protein involved in the clearance of all-trans retinaldehyde from photoreceptor discs into the cytoplasm for reduction to its alcohol.4,5

The ABCA4 variant p.Asn1868Ile (c.5603A>T) has long been shown to be enriched in those with retinal disease compared to controls,4 but its pathogenicity is typically dependent on the co-occurrence of another cis-acting variant.7,8 The common allele frequency in European populations, which approaches 7%,9,10 precludes it acting by itself as a fully penetrant recessive allele. Work by Zernant et al.11, and others7,8 did show that the variant, when in trans with a distinct ABCA4 variant explains a proportion of mildly affected patients. Furthermore, functional assays show the allele impairs ATP-driven transport of retinaldehyde conjugates.3

The purpose of this study is to determine whether the p.Asn1868Ile allele is associated with any subclinical pathogenic effects in the macula within the general population that do not have ABCA4 retinopathy, using a large population-based cohort.
Participants from the UK Biobank data resource were used for this investigation. The UK Biobank is a volunteer cohort in the United Kingdom with genetic, medical, and lifestyle information for 503,325 participants aged between 40 and 69 years of age at recruitment. An enhanced ocular assessment including spectral-domain optical coherence tomography (OCT) imaging was performed on a subset of UK Biobank Eye and Vision Consortium participants.

**Methods**

This is a cross-sectional analysis using the UK Biobank data resource.

**Ethical Approval**

All participants included in this analysis provided full informed consent in accordance with ethical approval granted and overseen by the UK Biobank Ethics and Governance Council. The UK Biobank study was conducted with the approval of the North-West Research Ethics Committee (ref 06/MRE08/65), in accordance with the principles of the Declaration of Helsinki. This research has been conducted using the UK Biobank Resource under Application Number 2112.

**Participants**

All participants included in this analysis were confirmed to be of European ancestry using principal component analysis. All included subjects were part of the ~200,000 interim, exome data release and the subset of participants who underwent macular spectral-domain OCT imaging. Prior to the application of exclusion criteria, a total of 37,586 participants were included for this analysis. The selection criteria for participants used in this study are outlined in Figure 1.

**Genotyping**

Participants included in this analysis were genotyped using whole-exome sequencing performed by the UK Biobank Exome Sequencing Consortium. Sequencing used the GRCh38 assembly with an average of 20× coverage at 95.6% of sites. This included direct genotyping of the c.5603A>T, p.Asn1868Ile variant.

**Phenotyping and Exclusion Criteria**

Macular spectral-domain OCT imaging was performed using the Topcon (Topcon GB, Newbury, Berkshire, UK) 3D OCT1000 Mark II. Imaging was performed in a dark room without pupil dilation using the three-dimensional 6 × 6-mm² macular volume scan mode (512 A scans per B scan; 128 horizontal B scans in a raster pattern). The right eye was scanned first. Version 1.6.1.1 of the Topcon Advanced Boundary Segmentation (TABS) algorithm was used to segment the retinal layers and calculate the thickness of each layer across retinal fields or subfields in early treatment diabetic retinopathy study (ETDRS) subfields. Various segmentation indicators and quality metrics are calculated during this process, consisting of image quality score; inner limiting membrane (ILM) indicator, which indicates the minimum localized edge strength around the ILM boundary across the scan; valid count, which measures the degree of clipping in the OCT scan’s z-axis; and the minimum motion correlation and maximum motion factor, which calculate the Pearson correlations and absolute differences between the nerve fiber layer and full retinal thickness from each set of consecutive B-scans, which identifies blinks, eye motion artifacts, and segmentation failures.

The segmented layers used as phenotypes for this analysis are summarized in Table 1, and the scan quality metrics used as outcome phenotypes for this analysis are summarized in Supplementary Table S1. The mean value for both eyes was used as the final phenotype.

The best-corrected visual acuity was measured in both eyes using logMAR at a distance of 4 m, or 1 m if the participant was unable to read any letters at 4 m. The mean value of both eyes was used as the final phenotype for analysis.

Strict quality control criteria were applied for the OCT-derived measures, based on previously implemented methods. In brief: image quality score <45, worst 20% for ILM indicator, valid count, minimum motion correlation, maximum motion delta, and maximum motion factor. These strict cutoffs were selected to ensure poor-quality scans were excluded as any artifacts arising from low scan quality would reduce sensitivity of the analyses to detect subclinical effects. Additionally, participants were excluded if they reported one of the following oculocutaneous pathologies that may influence retinal thickness: high myopia (−6 diopters), high hyperopia (>6 diopters), glaucoma, ocular hypertension, and AMD. Following these exclusion criteria, 26,558 participants were included in the final data set. A breakdown of the numbers included in the final data set is provided in Table 2.

**Statistical Analysis**

All statistical analyses were performed in R v3.6.3. Two models were used to test for association between p.Asn1868Ile genotype and ocular outcome (macula thickness, scan quality, and visual acuity).

The first was a linear model, corresponding to an additive effect at the locus, adjusted for age and sex, in

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>56.9</td>
<td>8.0</td>
</tr>
<tr>
<td>Sex, female, %</td>
<td>52.2</td>
<td>NA</td>
</tr>
<tr>
<td>Total retinal layer</td>
<td>277.9</td>
<td>14.8</td>
</tr>
<tr>
<td>RNFL</td>
<td>28.4</td>
<td>4.8</td>
</tr>
<tr>
<td>GC-IPL</td>
<td>74.4</td>
<td>6.2</td>
</tr>
<tr>
<td>RPE</td>
<td>25.9</td>
<td>8.6</td>
</tr>
<tr>
<td>Photoreceptor layer</td>
<td>47.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Visual acuity (logMAR)</td>
<td>0.008</td>
<td>0.165</td>
</tr>
</tbody>
</table>

Units for thickness measurements are in microns. GC-IPL, ganglion cell–inner plexiform layer; RNFL, retinal nerve fiber layer.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Pre-QC, n</th>
<th>Post-QC, n</th>
<th>% Removed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous T</td>
<td>32,629</td>
<td>23,026</td>
<td>29.4</td>
</tr>
<tr>
<td>Heterozygous</td>
<td>4770</td>
<td>3396</td>
<td>28.8</td>
</tr>
<tr>
<td>Homozygous A</td>
<td>187</td>
<td>156</td>
<td>27.3</td>
</tr>
</tbody>
</table>

“% removed” is the percentage of participants removed from each genotype grouping during quality control (QC).
which the ocular outcome was the outcome variable, and p.Asn1868Ile genotype was coded as the number (0, 1, 2) of minor alleles, c.5603A, present in the participant's genotype.

The second model was a recessive model, adjusted for age and sex, in which the ocular outcome was the outcome variable. However, in this model, p.Asn1868Ile genotype was coded as 0 for participants with either TT or TA genotypes, and participants with AA genotypes were coded as 1. This model identifies associated effects when allelic effects follow a recessive model of inheritance.

The following equation summarizes both models:

\[
\text{Ocular outcome} \sim \text{p.Asn1868Ile genotype} + \text{age} + \text{sex}
\]

Power calculations of the smallest effect sizes identifiable for each trait are provided in Supplementary Table S2.
RESULTS

The number of participants with each p.Asn1868Ile genotype is shown in Table 2. The p.Asn1868Ile genotypes within the UK Biobank (Table 2) are in Hardy–Weinberg equilibrium ($\chi^2 = 0.792$, $P = 0.37$) indicating that this cohort is unlikely subject to strong sampling bias for the purpose of this study.

Participants carrying the p.Asn1868Ile allele were not more likely to be excluded due to poor-quality scans than those without (Table 2, $\chi^2 = 1.17$, $P = 0.56$). Therefore, all results reported will be derived from the data set after the application of exclusion criteria.

The linear model identified no significant association between the total retinal thickness and p.Asn1868Ile allele prior to corrections for multiple testing ($\beta = -0.12$, SE = 0.25, $P = 0.62$) (Fig. 2a). There was no evidence of association for specific segmentations of the retina, including the retinal nerve fiber layer ($\beta = -0.12$, SE = 0.79, $P = 0.13$) (Fig. 2b), ganglion cell–inner plexiform layer ($\beta = -4.4 \times 10^{-3}$, SE = 0.10, $P = 0.97$), and, most importantly, the RPE ($\beta = 0.097$, SE = 0.15, $P = 0.51$) (Fig. 2c) and the photoreceptor layer ($\beta = -0.017$, SE = 0.049, $P = 0.72$) (Fig. 2d), which are the retinal layers most affected in ABCA4 retinopathy. All linear association results are summarized in Table 3.

![Violin plots](image-url)

**Figure 2.** The "A" allele is referring to the allele at the genotype. (a) Violin plot of association results between p.Asn1868Ile and total retinal thickness. (b) Violin plot of association results between p.Asn1868Ile and retinal nerve fiber layer. (c) Violin plot of association results between p.Asn1868Ile and retinal pigment epithelium. (d) Violin plot of association results between p.Asn1868Ile and the photoreceptor layer. For all panels, the white box in the center of each violin shows the interquartile range and the central line in the white box is the median. The colored region around this box is a density plot capturing 99.3% of values.
We tested for an association using a linear model between p.Asn1868Ile and all eight OCT quality control (QC) measures, which might serve as a proxy for structural abnormalities in the retina. Prior to corrections for multiple testing, no significant association was identified for image quality ($\beta = -0.048$, $SE = 0.15$, $P = 0.76$) (Supplementary Fig. S1) or any of the other seven QC metrics (Supplementary Table S3).

The final test using the linear model did not identify any association between p.Asn1868Ile and visual acuity ($\beta = -6.0 \times 10^{-4}$, $SE = 3.0 \times 10^{-3}$, $P = 0.83$).

Finally, we repeated all association tests using the recessive model. No association was identified between all retinal thickness measurements or visual acuity under the assumptions of both an additive and a recessive model.

We found that the two are not associated; it may result from insufficient statistical power. However, given our large cohort of 26,558 participants, this study was sufficiently powered to identify small effects (Supplementary Table S2); therefore, these negative results provide strong evidence that the p.Asn1868Ile allele is not associated with subclinical retinal effects among the general population. The absence of significance without applying corrections for multiple testing further strengthens this conclusion.

**DISCUSSION**

In this study, we provide evidence that the *ABCA4* retinopathy-associated missense allele, p.Asn1868Ile, is not associated with retinal structure (as quantified by macular layer thicknesses) or central retinal function (as quantified by visual acuity) within the general population, under the assumptions of both an additive and a recessive model.

Across many diseases, mild variants are often associated with subclinical effects in endophenotypes for the disease in carriers. Negative results in this analysis are important as they show that p.Asn1868Ile pathogenicity functions entirely through interactive effects and not through additive effects.

Negative association results do not necessarily mean that the two are not associated; it may result from insufficient statistical power. However, given our large cohort of 26,558 participants, this study was sufficiently powered to identify small effects (Supplementary Table S2); therefore, these negative results provide strong evidence that the p.Asn1868Ile allele is not associated with subclinical retinal effects among the general population. The absence of significance without applying corrections for multiple testing further strengthens this conclusion.

**ACKNOWLEDGMENTS**

Supported by the Wellcome Trust (Grant 206619_Z_17_Z) and The Macular Society, as well as the National Institute for...
Health and Care Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and University College London Institute of Ophthalmology. This research was conducted by using the UK Biobank Resource under application number 2112. UK Biobank was established by the Wellcome Trust Medical Charity, Medical Research Council, Department of Health, Scottish Government, and Northwest Regional Development Agency. It also had funding from the Welsh Assembly Government, British Heart Foundation, and Diabetes UK. The views expressed are those of the authors and not the funding organizations.

GA is funded by the National Institute of Health Research Biomedical Research Centre (NIHR-BRC) at Moorfields Eye Hospital and UCL Institute of Ophthalmology, a Fight For Sight UK Early Career Investigator Award (5045/46) and NIHR-BRC at Great Ormond Street Hospital Institute for Child Health.

Disclosure: M.J. Simcoe, None; G. Arno, None; P.G. Hysi, None; T. Ko, None; M. Michaelides, None; C.J. Hammond, None; P.J. Patel, None; O.A. Mahroo, None; A.R. Webster, None

References


